aTAG 2139

aTAG 2139 is a degrader of MTH1 fusion proteins for use within the aTAG system. Comprises a ligand selective for MTH1, a linker and the cereblon-binding ligand Thalidomide (Cat. No. 0652). Induces highly potent and selective degradation of fusion proteins after a 4 h incubation (DC₅₀ = 0.27 nM; D_max = 92.1%). Cell-permeable. Suitable for in vitro and in vivo applications.

Negative control aTAG 2139-NEG (Cat. No. 7575) also available.

Mouse DMPK properties are provided in the supplementary file (see below).

MTH1 can be expressed as a fusion with a target protein of interest using genome engineering techniques via CRISPR-mediated locus-specific knock-in. See protocol for more information.